OBiO Tech(SH:688238) Zhong Zheng Wang·2025-04-18 03:32Core Insights - The company reported a revenue of 248 million yuan for 2024, marking a year-on-year growth of 21.16% [1] - The establishment of the "Regenerative Medicine Center" signifies a strategic expansion into cell therapy, potentially becoming a new growth highlight for the company [1] - The completion of the first phase of the Lingang Industrial Base enhances the company's production capabilities, positioning it as a leading provider of one-stop services for cell and gene therapy product development [1] Financial Performance - The company achieved CDMO sales revenue of 135 million yuan, an increase of 26.12% compared to the previous year [2] - New CDMO business orders exceeded 270 million yuan during the year, indicating strong demand and order progress [2] - The company assisted clients in obtaining 12 IND approvals within the reporting period, contributing to a total of 44 IND approvals to date [2] Strategic Initiatives - The company initiated a share repurchase plan in 2025, having repurchased approximately 18.73 million shares, accounting for 2.8853% of total shares, with an average price of 5.34 yuan per share [2] - Part of the repurchased shares is intended for equity incentives, aiming to align the interests of the core team with the company's long-term development [2] - The company continues to leverage its diverse technical capabilities across various cell therapy fields, including oncolytic viruses, AAV gene therapy, CAR-T/NK, and stem cells [2]